Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma

ELOQUENT-2 Japanese patient subanalysis

K. Suzuki, K. Sunami, K. Ohashi, S. Iida, Takehiko Mori, H. Handa, K. Matsue, M. Miyoshi, E. Bleickardt, M. Matsumoto, M. Taniwaki

Research output: Contribution to journalLetter

3 Citations (Scopus)
Original languageEnglish
Article numbere540
JournalBlood Cancer Journal
Volume7
Issue number3
DOIs
Publication statusPublished - 2017 Mar 10

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma : ELOQUENT-2 Japanese patient subanalysis. / Suzuki, K.; Sunami, K.; Ohashi, K.; Iida, S.; Mori, Takehiko; Handa, H.; Matsue, K.; Miyoshi, M.; Bleickardt, E.; Matsumoto, M.; Taniwaki, M.

In: Blood Cancer Journal, Vol. 7, No. 3, e540, 10.03.2017.

Research output: Contribution to journalLetter

Suzuki, K, Sunami, K, Ohashi, K, Iida, S, Mori, T, Handa, H, Matsue, K, Miyoshi, M, Bleickardt, E, Matsumoto, M & Taniwaki, M 2017, 'Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis', Blood Cancer Journal, vol. 7, no. 3, e540. https://doi.org/10.1038/bcj.2017.18
Suzuki, K. ; Sunami, K. ; Ohashi, K. ; Iida, S. ; Mori, Takehiko ; Handa, H. ; Matsue, K. ; Miyoshi, M. ; Bleickardt, E. ; Matsumoto, M. ; Taniwaki, M. / Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma : ELOQUENT-2 Japanese patient subanalysis. In: Blood Cancer Journal. 2017 ; Vol. 7, No. 3.
@article{20a43c18fba14065a77fef00386c8f7c,
title = "Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis",
author = "K. Suzuki and K. Sunami and K. Ohashi and S. Iida and Takehiko Mori and H. Handa and K. Matsue and M. Miyoshi and E. Bleickardt and M. Matsumoto and M. Taniwaki",
year = "2017",
month = "3",
day = "10",
doi = "10.1038/bcj.2017.18",
language = "English",
volume = "7",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma

T2 - ELOQUENT-2 Japanese patient subanalysis

AU - Suzuki, K.

AU - Sunami, K.

AU - Ohashi, K.

AU - Iida, S.

AU - Mori, Takehiko

AU - Handa, H.

AU - Matsue, K.

AU - Miyoshi, M.

AU - Bleickardt, E.

AU - Matsumoto, M.

AU - Taniwaki, M.

PY - 2017/3/10

Y1 - 2017/3/10

UR - http://www.scopus.com/inward/record.url?scp=85015231066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015231066&partnerID=8YFLogxK

U2 - 10.1038/bcj.2017.18

DO - 10.1038/bcj.2017.18

M3 - Letter

VL - 7

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 3

M1 - e540

ER -